SIWA Therapeutics, Inc., a privately held biotechnology company developing a family of monoclonal antibodies to prevent, slow or reverse aging, aging-related and degenerative diseases by reducing senescent cells, announced today that Dr. Thomas Tang has joined its Scientific Advisory Board. Dr. Tang is the CEO of First Dimension BioSciences, a genetic information database company focusing on cancer genomes to establish a statistical compendium of mutation profiles in a state-of-the-art computational data center. He has over 20 years of experience in genomics and bioinformatics research.
“Dr. Tang’s addition to the SIWA team will resurrect a productive past partnership,” said Lewis Gruber, co-founder and chief executive officer of SIWA. ‘Tom was one of the early scientists at my first company, Hyseq, Inc. He was a key player in developing Hyseq’s genomics database which grew to be one of the largest in the 1990s. As our antibody has been shown to statistically significantly reduce senescent cells and to decrease cancer metastasis in mice, we and a university partner are focusing on certain cancers. Dr. Tang’s cancer genomic database expertise will be invaluable to us, particularly since we are helping build a senescent-cell related database.”
“I am pleased to be working with Lewis again in developing yet another database,” Dr. Tang said. “Collaborating should enhance SIWA’s ability to develop drugs that fight cancer and other aging and aging-related diseases.”
“Dr. Tang’s extensive experience in building major databases will be instrumental in helping us move data on senescent cells in various tissues into an easily usable database that we are helping develop,” Gruber added. “We believe that the database ultimately will become a useful tool in determining dosages for our drugs as well as determining where to apply those drugs.”
Dr. Tang has published dozens of research papers in leading scientific journals and procured 90 issued U.S. patents. He has led scientists in discovering more than 20 percent of all human genes. He has discovered and named four important gene families, including an insulin-like family of human hormones, a GPCR-like membrane protein family, a family of neural growth factors, and a family of stem cell growth factors. His degrees include a BS in Biology and a Ph.D. in Mathematics.
ABOUT SIWA Therapeutics, Inc.
SIWA is a privately held biotechnology company based in Chicago. SIWA has shown that its monoclonal antibody, SIWA 318, targets and reduces senescent cells in animal models without observable side effects of treatment. Although senescent cells are causally implicated in a wide variety of diseases including neurodegenerative diseases, autoimmune conditions, and infectious diseases, SIWA’s current therapeutic focus is on certain cancers. www.siwatherapeutics.com
For more information, contact:
Forward Looking Statements
Certain information contained in this press release represents or is based upon forward -looking statements or information. Forward-looking statements and information can be identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “continue” or “believe” or the negative thereof or other variations or comparable terminology. Such forward-looking statements include statements regarding SIWA’s expectations concerning, among other things the ability to advance into clinical trials. Various factors may cause differences between SIWA’s expectations and actual results. Any forward-looking statements that are made in this press release speak only as of the date of this press release and SIWA assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.